2008 related articles for article (PubMed ID: 12479591)
1. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
2. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
4. [G-CSF in oncology].
Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
[TBL] [Abstract][Full Text] [Related]
5. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
6. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
8. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.
Herbst C; Naumann F; Kruse EB; Monsef I; Bohlius J; Schulz H; Engert A
Cochrane Database Syst Rev; 2009 Jan; (1):CD007107. PubMed ID: 19160320
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
Aapro M; Crawford J; Kamioner D
Support Care Cancer; 2010 May; 18(5):529-41. PubMed ID: 20191292
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
12. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
Lyman GH
J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
15. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
17. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
Gómez Raposo C; Pinto Marín A; González Barón M
Clin Transl Oncol; 2006 Oct; 8(10):729-34. PubMed ID: 17074671
[TBL] [Abstract][Full Text] [Related]
18. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
Frampton JE; Faulds D
Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371
[TBL] [Abstract][Full Text] [Related]
19. Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children.
Kim H; Mousa SA
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):977-986. PubMed ID: 35929962
[TBL] [Abstract][Full Text] [Related]
20. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
